Net income reached $25.4 million, or 30 cents per share, marking a significant improvement over the $17.8 million, or 23 cents per share, recorded during the same period last year. Revenue jumped 55% to $243.6 million, comfortably outpacing the $228.7 million consensus estimate from FactSet analysts.

Chief Executive Sanj Patel attributed the momentum to a growing base of both new and repeat prescribers for Arcalyst, an injectable medication used to manage inflammatory conditions. Following this patient uptake, the company adjusted its fiscal 2026 outlook for the drug, projecting annual sales between $980 million and $995 million.